Effects of a Hemp Product on the Pharmacokinetics and Pharmacodynamics of Clopidogrel
ConditionInteraction
Trial statusRecruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age21-64
SponsorWashington State University
About this trial
The goal of this clinical trial is to determine how two different doses of cannabidiol (CBD), given as a hemp product, change the blood concentrations of the drug clopidogrel in the body. Results will be used to help design future studies and to assist healthcare providers in informing their patients about the safe use of CBD.
Eligibility criteria
Qualifiers
21-64 years old and healthy;
Confirmed by genetic test to be a CYP2C19 normal, rapid, or ultra-rapid metabolizer;
Not taking any medications (prescription and non-prescription, including clopidogrel) or dietary supplements/botanical products known to alter the pharmacokinetics of cannabis and/or clopidogrel;
Have taken hemp or cannabis (in any form) before and tolerated it well;
Disqualifiers
Under the age of 21 or over the age of 64;
Any major illness;
Pregnant or nursing;
History of allergy or intolerance to cannabis or clopidogrel;
Trial design
Treatments tested in this trial
- Cannabidiol in the form of hemp
- Clopidogrel
Treatment groups
24 Participants
are divided into 3 treatment groupsSponsors and collaborators
Washington State University
Lead sponsor
Office of Dietary Supplements (ODS)
Collaborator
National Center for Complementary and Integrative Health (NCCIH)
Collaborator
Source ClinicalTrials.gov